Pfizer Q1 profit, revenue soar on COVID-19 vaccine sales

, which has been Pfizer’s top seller for about a year, brought in more than $13 billion in sales in the quarter. The pill treatment Paxlovid, which launched late last year, added another $1.5 billion.

Sales of that vaccine topped analyst expectations for the quarter, but revenue from Paxlovid fell short. Revenue from both products will likely wind up exceeding forecasts, Mizuho Securities USA analyst Dr. Vamil Divan said in a research note. He noted that current projections only include contracts the company signed as of mid-April.Outside Comirnaty and Paxlovid, Pfizer makes several cancer treatments, other vaccines and internal medicine drugs like Eliquis, for preventing blood clots and strokes.

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Prepare for a COVID-19 summer surge, medical experts warnCOVID-19 cases have been slowly increasing in nearly every state as the highly contagious BA.2 subvariant spreads in the U.S. Most of those cases have been relatively mild, and experts say vaccination continues to provide strong protection against severe illness. But it's the ability of the virus to change that makes arresting COVID-19 challenging. We've moved on. The 'experts' need to come up with something else. This sounds like parody or satire to me. Nothing shocking or scary about it anymore. 'Surges' are part of the new normal. Moving on ....
Source: FOX4 - 🏆 289. / 63 Read more »